Mentor Capital, Inc. (OTC Markets: MNTR) announced that it has initiated
investment in the Medical Marijuana market. “The ‘munchies’ are a
godsend to cancer sufferers who just stop eating food that tastes like
wood and leaves them nauseous,” explains Mentor CEO, Chester
Billingsley. “In the days of clans and caves, elders with cancer that
stopped eating improved the chances of their grandchildren surviving the
lean times. That former evolutionary advantage now weakens cancer
patients and decreases their ability to handle chemo and other therapies
that today may save them.”
Twenty states have already legalized medical marijuana. However, the key
development that cleared the way for Mentor Capital, Inc. to direct
funds toward cannabis in medicine was the August 29, 2013 announcement
by the Justice Department that it won’t challenge state laws that
legalize marijuana.
“Yesterday, I talked to a mother whose 6’4” son had dwindled to 120 lbs.
We have the medical knowledge and financial ability to help here and
ethically lead the sector forward, so we must,” concludes Billingsley.
About Mentor Capital: By acquisition or stock purchase, Mentor
Capital, Inc. seeks to invest in leading companies, including public and
private medical marijuana companies, which improve or reduce the cost of
medical treatments, especially in the fight against cancer. Additional
important information is presented at: www.MentorCapital.com
Forward Looking Statements, Safe Harbor and Risk Descriptions are
Incorporated by Reference from the MNTR Company Web Site above.
Copyright Business Wire 2013